Karen Knudsen: I’ve taken the helm of Parker Institute for Cancer Immunotherapy (PICI) as CEO

About the role

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy (PICI). She previously served as the Executive Strategic Advisor and Immediate Past CEO of the American Cancer Society (ACS).

Responsibilities

• Accelerate the timeline from bold discovery to patient impact
• Lead an organization dedicated to high-risk, high-reward science and clinical testing
• Ensure promising ideas are not stalled through collaboration with top scientists, clinicians, and institutions
• Support the development of innovative therapies targeting difficult-to-treat cancers
• Work towards translating scientific advancements into effective treatments

Qualifications

• Career experience at the intersection of science, healthcare, strategy, and mission
• Leadership roles in major academic cancer centers and national organizations
• Experience working with partners across biotech and policy sectors

Benefits

• Access to a network of top scientists and clinicians
• Opportunities to advance clinical testing and company creation
• Support for the development of innovative therapies targeting difficult-to-treat cancers

Pay

The pay details are not specified in the provided information.

Schedule

The schedule details are not specified in the provided information.

Skills

• Strong leadership skills
• Experience in the intersection of science, healthcare, strategy, and mission
• Collaborative approach to advancing scientific research and clinical trials
• Ability to navigate complex organizational structures and partnerships

Benefits

• Flexible work arrangements
• Professional development opportunities
• Health and wellness programs

Company Information

The Parker Institute for Cancer Immunotherapy (PICI) was founded ten years ago through the visionary leadership of Sean Parker. It is a national model that funds high-risk, high-reward science and ensures that promising ideas don’t stall. PICI supports the development of innovative therapies targeting difficult-to-treat cancers through mRNA cancer vaccines and next-gen immunotherapy strategies.